There is no drug by the name of Kyzatrex currently approved or marketed in Mexico.
What drugs are available for the condition Kyzatrex might treat?
The drug Kyzatrex, also known by the investigational name MK-801, is being developed as a potential treatment for Alzheimer's disease [1]. Treatments for Alzheimer's disease available in Mexico include medications that target symptoms, such as cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) and memantine [2]. These medications aim to improve cognitive function and manage behavioral changes associated with the disease.
When might Kyzatrex be available in Mexico?
As Kyzatrex is still an investigational drug, its availability in Mexico would depend on successful clinical trials, regulatory approval by Mexican health authorities (COFEPRIS), and commercialization efforts by its developer [1]. Information regarding the timeline for such approvals is not yet publicly available.
Who is developing Kyzatrex?
Kyzatrex is being developed by Merck [1]. Merck is a global biopharmaceutical company involved in the research and development of new medicines.
How is Kyzatrex being tested for Alzheimer's disease?
Kyzatrex is being evaluated in clinical trials for its potential to treat Alzheimer's disease. Merck is conducting studies to assess its safety and efficacy [1]. Specific details about ongoing or planned trials in Mexico are not publicly disclosed.